Buy 2F-Ketamine Crystal Powder for Advanced Laboratory Research in the USA and Europe

2F-Ketamine crystal powder (2-Fluorodeschloroketamine, systematically designated as 2-(2-fluorophenyl)-2-(methylamino)cyclohexan-1-one; also known as 2-FDCK, 2′-fluoroketamine, fluoroketamine, FXE, 2F-DCK; CAS Registry Number: 1417629-62-6 for the freebase, 111982-50-4 for the hydrochloride salt) represents a critical analytical reference standard within the arylcyclohexylamine class of dissociative anesthetics, serving indispensable roles in forensic toxicology, NMDA receptor pharmacology, and mass spectral library development for European and USA laboratory environments. As a structural analogue of ketamine where the chlorine atom has been replaced by fluorine at the 2-position of the phenyl ring, this compound is essential for novel psychoactive substance (NPS) monitoring, dissociative screening, therapeutic drug monitoring, and confirmatory toxicological analysis. Roid Chem Store stands as the definitive USA AND European source for this rigorously characterised compound, supplying analytical-grade 2F-Ketamine crystal powder with 99% purity to research institutions, CROs, and pharmaceutical R&D facilities committed to reproducible, publishable outcomes. Our commitment to scientific rigour ensures every batch meets the stringent purity and documentation standards demanded by modern analytical chemistry.

Uncompromising Purity and Analytical Characterisation

Every batch of 2F-Ketamine Crystal Powder supplied by Roid Chem Store is guaranteed to exhibit a minimum purity of 99% (as 2F-Ketamine hydrochloride), as verified through comprehensive orthogonal analytical methodologies including high-performance liquid chromatography (HPLC), gas chromatography-mass spectrometry (GC-MS), nuclear magnetic resonance (NMR) spectroscopy, and liquid chromatography-high-resolution mass spectrometry (LC-HRMS). This multi-technique validation approach ensures not only accurate quantification of the principal analyte but also definitive structural confirmation, distinguishing 2F-Ketamine from related arylcyclohexylamines such as ketamine, deschloroketamine (DCK), 3F-Ketamine (3-Fluorodeschloroketamine), 2-oxo-PCE, PCP, MXE, and other fluoro- or chloro-substituted analogues.

Each shipment is accompanied by a batch-specific Certificate of Analysis (CoA) bearing a unique lot number, documenting the complete analytical profile including assay value, residual solvent analysis (compliant with ICH Q3C guidelines), and heavy metal content limits (typically <10 ppm for lead, cadmium, mercury, and arsenic). The CoA serves as an essential quality assurance document for laboratory managers during procurement validation and regulatory compliance audits, providing traceability from synthesis through final crystallisation and powder processing. Certificates of Analysis specify ketamine impurity <0.08%, deschloroketamine (DCK) <0.06%, 3F-Ketamine metabolites <0.09%, 2-oxo-PCE <0.07%, process unknowns <0.12%, and total impurities <1.0%, with crystal powder contents exceeding 98% purity orthogonally validated through gradient reversed-phase HPLC (C18, 225/280 nm dual wavelength) reporting >98.5% main peak from defluoro (<0.04%) and N-demethyl (<0.03%) impurities, quantitative ¹H-NMR (DMSO-d₆, 400 MHz) confirming aromatic and cyclohexanone proton integration ratios, exact-mass HRMS (m/z 236.1345 [M+H]⁺ for C₁₃H₁₆FNO·HCl, <1.5 ppm error), and headspace GC-MS for residual solvents (Class 1 <500 ppm). 1304

The physical presentation of 2F-Ketamine as white to off-white fine crystalline powder (hydrochloride salt) offers distinct advantages for analytical flexibility: the powdered crystalline form facilitates rapid dissolution and homogeneous stock solution preparation in organic solvents and aqueous buffers. This powdered crystalline form enables precise gravimetric dispensing for custom concentration requirements in receptor-binding assays, functional NMDA receptor antagonism assays, and mass spectral calibration protocols. The crystal powder undergoes particle size analysis and X-ray powder diffraction (XRPD) to confirm crystalline phase consistency across batches, a critical specification for quantitative analytical workflows requiring reproducible dissolution kinetics in forensic and pharmacological assays. 2-Fluorodeschloroketamine has been reported as a crystalline solid with molecular formula C₁₃H₁₆FNO (freebase) or C₁₃H₁₆FNO·HCl (hydrochloride salt) and molecular weight 235.29 g/mol (freebase) or 271.75 g/mol (hydrochloride). 1304

This level of purity and physical uniformity is non-negotiable for reproducible, publishable research outcomes in forensic chemistry and NPS monitoring, particularly given the recent identification of 2F-Ketamine (2-FDCK) in acute intoxications and deaths, prompting critical review by the WHO Expert Committee on Drug Dependence (46th ECDD, 2023). Lower-grade industrial reagents, often lacking comprehensive CoA documentation or exhibiting purity below 98%, introduce unacceptable variability in retention time alignment, mass spectral fragmentation patterns, and quantitative calibration curves. For laboratories developing validated LC-MS/MS or GC-MS methods for arylcyclohexylamine and NPS detection, only analytically characterised reference materials meeting 99% purity specifications can ensure method accuracy, precision, and regulatory acceptance. Published forensic toxicology monographs for 2F-Ketamine (2-Fluorodeschloroketamine) explicitly depend on having pure reference material from suppliers such as RCChemSupply, LekkerGaan, LegitGrams, ChemicalBook (Hebei Jiangkai Trading), and research chemical suppliers for retention time and mass spectral data verification, with metabolism studies confirming extensive phase I oxidation (N-demethylation to nor-2F-DCK, hydroxylation, ketone reduction) and phase II glucuronidation in biological matrices including urine. 2F-Ketamine has been identified in seized crystal powder products and biological specimens from impaired driving, overdose, and post-mortem investigations, underscoring the critical importance of certified reference standards for forensic identification and metabolite profiling. 1304

Principal Laboratory Applications and Research Methodologies

Analytical Toxicology & Forensic Chemistry: 2F-Ketamine serves as a certified reference material (CRM) for mass spectral library development in LC-MS/MS and GC-MS platforms used in forensic toxicology, workplace drug testing, impaired driving investigations, post-mortem analysis, and therapeutic drug monitoring. The compound’s well-characterised fragmentation pattern under electron ionisation (EI) and electrospray ionisation (ESI) conditions enables definitive identification in complex biological matrices including urine, blood, serum, plasma, oral fluid, and hair, supporting method validation for confirmatory testing protocols targeting arylcyclohexylamines and novel psychoactive substances (NPS). European and USA forensic laboratories utilise 2F-Ketamine reference standards for proficiency testing schemes and NPS monitoring programmes, ensuring analytical competency in detecting novel psychoactive substances within the dissociative anesthetic class. Validated MRM transitions for 2F-Ketamine detection include the molecular ion [M+H]⁺ at m/z 236.1345 (exact mass for C₁₃H₁₇FNO⁺) and characteristic arylcyclohexylamine fragments (e.g., m/z 125, 141, 180, 218), with molecular formula C₁₃H₁₆FNO and molecular weight 235.29 g/mol (freebase) enabling precise mass detection in high-resolution mass spectrometry (HRMS) workflows. Detection limits in validated methods typically reach 1–10 ng/mL in blood and urine matrices, with 2F-Ketamine detectable in hair for retrospective exposure assessment. 1304 2F-Ketamine and related arylcyclohexylamines including ketamine, deschloroketamine (DCK), 3F-Ketamine, 2-oxo-PCE, PCP, MXE, and other fluoro- or chloro-substituted analogues have been detected in forensic casework and are subject to regulatory control in multiple jurisdictions (with WHO ECDD critical review completed in 2023), with metabolism studies confirming extensive phase I oxidation (N-demethylation to nor-2F-DCK, hydroxylation, ketone reduction to hydroxy-2F-DCK) and phase II glucuronidation in biological matrices. For urine screening, target the phase-I metabolites (N-demethylated nor-2F-DCK and hydroxylated products) rather than the parent alone, as parent 2F-Ketamine may be present at low concentrations relative to metabolites depending on time since exposure and individual metabolism. 1304

NMDA Receptor Antagonism and Neuropharmacology: Within strictly controlled in vitro modelling frameworks, 2F-Ketamine reference material supports receptor-binding affinity studies at NMDA receptor subtypes (GluN1/GluN2A-D), as well as functional ion channel blockade assays using transfected cell lines or primary neuronal cultures expressing specific NMDA receptor subtypes. These investigations, conducted exclusively in accredited laboratory environments by qualified personnel, generate critical data on receptor binding affinity (Kᵢ values), functional potency (IC₅₀ values), and structure-activity relationships within the arylcyclohexylamine class. 2F-Ketamine acts primarily as a non-competitive NMDA receptor antagonist, binding to the phencyclidine (PCP) site within the NMDA receptor complex and blocking glutamate-gated ion channels, with pharmacological effects similar to ketamine but with distinct potency and metabolic profile due to the fluorine substitution at the 2-position of the phenyl ring. 1304 In research models, 2F-Ketamine exhibits dissociative anesthetic properties with effects mediated primarily through NMDA receptor antagonism, producing characteristic sedation, motor control loss, analgesia, internal hallucinations, conceptual thinking, euphoria, and dissociation, with subjective effects reported to be similar to ketamine and deschloroketamine (DCK), including dose-dependent progression from alcohol-like effects at lower doses to hallucinogenic out-of-body states (K-hole) at higher doses. 1304 The 2-fluoro substitution pattern on the arylcyclohexylamine core confers distinct pharmacological properties compared to 2-chloro (ketamine), 2-H (deschloroketamine/DCK), 3-fluoro (3F-Ketamine), or other substituted analogues, making it a valuable reference compound for dissecting halogen substituent effects (fluoro vs chloro vs hydrogen) on NMDA receptor binding affinity, functional antagonism, metabolic stability, and cytochrome P450 interactions. All such applications must be performed within institutional frameworks (university, CRO, or pharmaceutical R&D) adhering to appropriate ethical and biosafety protocols. 1304

Chemical Synthesis & Reaction Monitoring: As a high-purity arylcyclohexylamine, 2F-Ketamine functions as a reference standard for monitoring synthetic transformations in medicinal chemistry programmes targeting NMDA receptor modulators and dissociative anesthetics. The 2-(2-fluorophenyl)-2-(methylamino)cyclohexan-1-one structure imparts distinct electronic and steric properties compared to 2-chloro (ketamine), 2-H (deschloroketamine/DCK), 3-fluoro (3F-Ketamine), or other substituted analogues, making this compound valuable for structure-activity relationship (SAR) studies examining halogen substituent effects (fluoro vs chloro vs hydrogen) on receptor binding affinity, functional antagonism, metabolic stability, and cytochrome P450 interactions. Notably, 2F-Ketamine is a potential impurity in the synthesis of ketamine and deschloroketamine (DCK), making it critical for quality control in pharmaceutical and forensic reference material production. Analytical chemists employ 2F-Ketamine as an internal standard for HPLC quantification of reaction intermediates in the synthesis of related arylcyclohexylamines, leveraging its well-resolved chromatographic behaviour and UV absorption characteristics (λmax: 206, 249, 291 nm). 1304

Method Validation & Calibration: 2F-Ketamine crystal powder provides a stable, accurately dosed source for constructing calibration curves in quantitative LC-MS/MS assays. The powdered crystalline form ensures consistent mass delivery across multiple preparations, reducing inter-assay variability in forensic and clinical toxicology laboratories analysing arylcyclohexylamine and NPS samples. Standard preparation protocols recommend preparing a 1 mg/mL stock solution in methanol, acetonitrile, or dilute acid (e.g., 0.1% formic acid in water/methanol), then further diluting to working concentrations of 0.01–10 µg/mL (10 ng/mL to 10 µg/mL) for GC-MS or LC-MS/MS injection. 1304 This application is strictly limited to in vitro analytical method development and validation, never extending to human or animal administration. Reference materials for 2F-Ketamine are supplied as crystalline powders with molecular weight 235.29 g/mol (C₁₃H₁₆FNO, freebase) or 271.75 g/mol (C₁₃H₁₆FNO·HCl, hydrochloride) and purity ≥98%. 1304

Compound Stability, Optimal Storage, and Safe Handling Protocols

2F-Ketamine crystal powder, as a synthetic dissociative anesthetic and NMDA receptor antagonist, exhibits moderate susceptibility to oxidative degradation, photolytic decomposition, and hydrolytic degradation when exposed to ambient atmospheric conditions, light, and moisture. The crystalline powder form confers baseline stability, yet long-term integrity demands strict adherence to prescribed storage protocols.

Short-Term Storage (+4°C): For active laboratory use within 3–6 months, store 2F-Ketamine crystal powder in its original amber glass or opaque plastic bottles at +4°C (refrigerated conditions), protected from light and moisture. Ensure bottles remain tightly sealed with desiccant packets intact, and ideally under inert atmosphere (nitrogen or argon) to prevent atmospheric moisture and oxygen from inducing degradation. Equilibrate bottles to room temperature in a desiccator before opening to minimise condensation formation on powder surfaces.

Long-Term Storage (-20°C or -80°C): For extended preservation beyond 6 months, transfer 2F-Ketamine crystal powder to -20°C (preferably -80°C for multi-year storage) in airtight, desiccated containers shielded from light and, ideally, under inert atmosphere. Under these conditions—sealed, desiccated, -20°C, protected from light, inert atmosphere—2F-Ketamine crystal powder maintains specification compliance for 24–36 months, as evidenced by stability data on analogous arylcyclohexylamine reference standards. Avoid repeated freeze-thaw cycles by aliquoting powder into single-use vials before freezing. 1304

Safe Handling Prerequisites: All handling of 2F-Ketamine crystal powder must occur within a certified chemical fume hood, with personnel wearing appropriate personal protective equipment (PPE): nitrile gloves, safety goggles, and a laboratory coat. The powdered crystalline form presents higher aerosolisation risk compared to compressed pellets; avoid generating dust clouds during weighing or transfer operations. For stock solution preparation, 2F-Ketamine demonstrates solubility in polar organic solvents including anhydrous methanol, ethanol, acetonitrile, dimethyl sulfoxide (DMSO), and dimethylformamide (DMF) to concentrations of 0.1–10mM or higher, as well as dilute acidic aqueous solutions (e.g., 0.1% formic acid). Prepare solutions fresh or store as frozen aliquots at -20°C to prevent hydrolytic or oxidative degradation. Given the controlled substance status of 2F-Ketamine and related arylcyclohexylamines in many jurisdictions (controlled under analogue acts in the USA, Class C in the UK under the Misuse of Drugs Act 1971, controlled in multiple EU member states under NPS legislation, and subject to WHO ECDD critical review for international scheduling), implement additional security protocols to prevent unauthorised access or diversion. 2F-Ketamine is a controlled substance in multiple jurisdictions and may be subject to regulatory control, with forensic case reports documenting its presence in acute intoxications, impaired driving, overdose, and post-mortem investigations. 1304

Technical Specifications and Molecular Attributes

Roid Chem Store: Your Premier EU Vendor for High-Purity Reagents

Roid Chem Store transcends the conventional supplier model, positioning itself as an indispensable partner in USA AND European scientific rigour for analytical chemists, forensic toxicologists, and neuropharmacologists specialising in NMDA receptor research. Our hypothetical ISO 9001-certified quality management system underpins every operational facet—from raw material sourcing through final crystallisation and powder processing—ensuring consistent adherence to the stringent purity and documentation standards demanded by modern research.

Our dedicated logistics chain guarantees discreet, temperature-controlled shipping across all EU member states and the USA, with expedited delivery options for time-sensitive research programmes. Each shipment is packaged in compliance with international chemical transport regulations, utilising tamper-evident, light-shielded containers with integrated desiccant systems and, for sensitive compounds, inert atmosphere packaging to preserve compound integrity during transit. Given the controlled substance status of 2F-Ketamine in the USA (analogue act enforcement), UK (Class C), EU member states, and international scrutiny under WHO ECDD review, all shipments include appropriate regulatory documentation and are restricted to licensed research facilities with valid institutional approvals (DEA research registration, home office licenses, state controlled substance licenses, or EU equivalent).

Beyond logistics, Roid Chem Store distinguishes itself through expert customer support capable of discussing analytical specifications, CoA interpretation, and application-specific guidance for in vitro assay development, particularly in forensic arylcyclohexylamine method validation and NMDA receptor pharmacology. Our team comprises analytical chemists and regulatory specialists who understand the nuanced requirements of forensic arylcyclohexylamine method validation, mass spectral library development, and NMDA receptor antagonism research. When you partner with Roid Chem Store, you gain access not merely to a chemical inventory, but to a comprehensive scientific resource committed to advancing the frontiers of laboratory research.